Overview
IDYA market data
Price History
IDYA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.28 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.07 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -74.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $22.38 – $40.58 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.6B · P/B 2.96 · P/S 15.17.
Company News
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59Benzinga · Aug 5, 2026, 6:18 PM
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60Benzinga · Aug 5, 2026, 1:20 PM
IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M EstimateBenzinga · Aug 4, 2026, 10:11 AM
Ideaya Biosciences Initiated Part 2 Monotherapy Expansion In Its Phase 1/2 Trial Of IDE892 In Mtap-Deleted Solid Tumors, With A Focus On Non-small Cell Lung Cancer And Pancreatic Ductal AdenocarcinomaBenzinga · Jul 27, 2026, 10:12 AM
IDEAYA Biosciences Announces Presentations At 2026 European Society of Medical Oncology Meeting October 23-27, Providing Updates Across IDEAYA's Clinical PipelineBenzinga · Jul 17, 2026, 1:04 PM
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48Benzinga · Jul 7, 2026, 4:20 PM
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $63Benzinga · Jul 7, 2026, 12:30 PM
8-K filing — IDEAYA Biosciences, Inc. (IDYA)SEC EDGAR · Jun 23, 2026, 8:05 PM
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price TargetBenzinga · Jun 12, 2026, 2:15 PM
Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionBenzinga · Jun 9, 2026, 12:10 PM